8-K: Ventyx VTX3232 Phase 2 Trial Shows Positive CV Risk Reduction

Ventyx Biosciences announced positive topline results from its Phase 2 study of VTX3232, demonstrating significant reductions in cardiovascular risk factors and good tolerability.

Summary

• VTX3232 monotherapy achieved approximately 80% reduction in high-sensitivity C-reactive protein (hsCRP) within the first week of dosing, sustained throughout the 12-week period.
• Participants treated with VTX3232 monotherapy showed a 78% reduction in hsCRP at week 12 relative to baseline in the modified analysis set (MAS), compared with a 3% increase in the placebo group (p<0.0001).
• In the full analysis set (FAS), VTX3232 monotherapy resulted in a 64% reduction in hsCRP at week 12 relative to baseline, compared with a 3% increase in the placebo group (p<0.0001).
• 69% of patients in the MAS achieved target hsCRP levels of less than 2mg/L, a critical threshold for determining residual inflammatory risk (p<0.0001).
• VTX3232 monotherapy demonstrated statistically significant reductions in IL-6 (p<0.0001) to median levels of 1.60ng/L, which is below the threshold for cardiovascular risk of 1.65ng/L.
• Statistically significant reductions were also observed in lipoprotein(a) (Lp(a)), fibrinogen, and erythrocyte sedimentation rate (ESR).
• Significant reduction in liver inflammation, independent of steatosis, was measured by cT1-corrected MRI.
• VTX3232 was safe and well tolerated in the Phase 2 study, with rates of adverse events comparable to placebo (46% for VTX3232 monotherapy vs. 49% for placebo, and 56% for VTX3232 + semaglutide vs. 56% for placebo + semaglutide).
• Treatment with VTX3232 monotherapy did not result in weight loss, nor did VTX3232 in combination with semaglutide demonstrate incremental weight loss over semaglutide alone.
• The combination of VTX3232 and semaglutide showed significant additional reductions in hsCRP, IL-6, fibrinogen, ESR, Lp(a), and liver inflammation over semaglutide alone.

Sentiment

Score: 9

Explanation: The trial results are overwhelmingly positive, demonstrating significant efficacy in reducing multiple cardiovascular risk factors with a favorable safety profile. The potential for VTX3232 as a standalone or adjunct therapy is highlighted, suggesting a strong future development path. The only minor negative is the lack of weight loss, which is not the primary target for this specific mechanism.

Positives

• VTX3232 demonstrated rapid and sustained reductions in hsCRP, achieving approximately 80% decrease from baseline within the first week and maintaining it over 12 weeks.
• A high proportion of participants (69%) achieved target hsCRP levels of less than 2mg/L, indicating effective reduction of inflammatory risk.
• Statistically significant reductions in IL-6 to levels below the cardiovascular risk threshold (1.65ng/L) were observed.
• VTX3232 treatment led to statistically significant reductions in other inflammatory biomarkers including Lp(a), fibrinogen, and ESR.
• Significant reduction in liver inflammation was observed, independent of liver fat content.
• VTX3232 exhibited a favorable safety and tolerability profile, with adverse event rates comparable to placebo.
• The combination of VTX3232 with semaglutide provided significant additional reductions in hsCRP, IL-6, Lp(a), and liver inflammation compared to semaglutide alone.

Negatives

• VTX3232 monotherapy did not result in weight loss.
• VTX3232 in combination with semaglutide did not demonstrate incremental weight loss over semaglutide alone.

Risks

• Potential delays in the commencement, enrollment, and completion of clinical trials.
• Dependence on third parties in connection with product manufacturing, research, and preclinical and clinical testing.
• Disruptions in the supply chain, including raw materials needed for manufacturing and animals used in research, and delays in site activations and enrollment of clinical trials.
• Early clinical trials not necessarily being predictive of future results, and interim results not necessarily being predictive of final results.
• The potential of one or more outcomes to materially change as a trial continues and more patient data become available, and following more comprehensive audit and verification procedures.
• Regulatory developments in the United States and foreign countries.
• Economic uncertainty in global markets caused by, among other things, geopolitical conditions, tariffs, military conflicts, and inflation volatility.
• Unexpected adverse side effects or inadequate efficacy of Ventyx's product candidates that may limit their development, regulatory approval and/or commercialization, or may result in recalls or product liability claims.
• Ventyx's ability to obtain and maintain intellectual property protection for its product candidates.
• The use of capital resources by Ventyx sooner than expected.

Future Outlook

VTX3232 holds promise for a new generation of oral anti-inflammatory therapies that, orthogonal to lipid lowering, may further reduce the risk of cardiovascular events. The combination of VTX3232 and semaglutide may serve as a powerful adjunct therapy to GLP-1 treatment in appropriate patients. The company plans to provide an update on its plans for the continued development of VTX3232 in future disclosures.

Management Comments

• Raju Mohan, PhD, Chief Executive Officer, stated: "We are very pleased with the results of this study where an ~80% reduction in hsCRP was achieved within the first week of dosing and maintained throughout the full 12-week dosing period in participants with measurable drug levels. VTX3232 also restored nearly 70% of study participants to target hsCRP levels of less than 2mg/L, the critical threshold for determining residual inflammatory risk. The effect we see in this study on IL-6, hsCRP, Lp(a), and other markers of aberrant systemic inflammation, leads us to believe VTX3232 holds promise for a new generation of oral anti-inflammatory therapies that, orthogonal to lipid lowering, may further reduce the risk of cardiovascular events."
• Mark Forman, MD, PhD, Chief Medical Officer, commented: "In this study, VTX3232 robustly inhibited the NLRP3 pathway, leading to significant reductions in the inflammatory cascade and demonstrated an encouraging safety profile. In the combination arm with semaglutide, we saw significant additional reductions in hsCRP, IL-6, Lp(a) and liver inflammation over semaglutide alone, suggesting the combination may serve as a powerful adjunct therapy to GLP-1 treatment in appropriate patients. These results support further development and VTX3232s potential to address the high burden of disease caused by inflammation."

Industry Context

The announcement positions VTX3232 as a transformative opportunity in cardiovascular disease treatment, leveraging growing evidence that directly targeting the NLRP3 inflammasome can significantly reduce underlying inflammation, a key driver of atherosclerosis, arrhythmias, heart failure, and related cardiometabolic disorders. This aligns with the 2025 ACC Statement on Inflammation and Cardiovascular Disease, which emphasizes the compelling and clinically actionable link between inflammation and atherosclerotic CVD, suggesting a shift towards anti-inflammatory therapies complementing established cholesterol-lowering treatments.

Comparison to Industry Standards

• VTX3232 reduced IL-6 levels to a median of 1.60ng/L, falling below the established cardiovascular risk threshold of 1.65ng/L, as referenced by Ridker, P.M. et. al. in Eur Heart J, 2018.
• Approximately 69% of patients achieved target hsCRP levels of less than 2mg/L, a critical threshold for determining residual inflammatory risk, consistent with findings from Ridker P.M. et. al. in Lancet 2023.
• The observed weight loss associated with semaglutide alone in the study was consistent with published 12-week data for semaglutide, such as that reported by JPH Wilding et al in NEJM (2021).
• The results are presented in the context of the 2025 ACC Statement on Inflammation and Cardiovascular Disease, which recommends targeting inflammation in primary and secondary cardiovascular prevention, indicating VTX3232's potential to meet a recognized medical need.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical trial results, potentially increasing company valuation and future revenue prospects.
• Patients with Obesity and Cardiovascular Risk Factors: Potential for a new, effective oral anti-inflammatory therapy to reduce cardiovascular event risk, especially as an adjunct to GLP-1 treatments.
• Healthcare Providers: New therapeutic option for managing cardiovascular inflammation, complementing existing treatments.

Next Steps

• Additional data from the Phase 2 trial will be presented at upcoming medical conferences.
• The Company will provide an update on its plans for the continued development of VTX3232 in future disclosures.

Key Dates

Recommendation

The positive Phase 2 topline data for VTX3232, showing significant and rapid reductions in multiple key cardiovascular inflammatory markers (hsCRP, IL-6, Lp(a)) with a favorable safety profile, de-risks the asset considerably. The potential for VTX3232 as a monotherapy or as an adjunct to GLP-1 treatments like semaglutide opens up a vast market opportunity in cardiovascular disease, addressing residual inflammatory risk. This strong clinical validation suggests a high probability of successful further development and commercialization, making it a compelling investment opportunity.

Keywords

Ventyx Biosciences, VTYX, VTX3232, NLRP3 inhibitor, Phase 2 trial, cardiovascular risk factors, obesity, hsCRP, IL-6, Lp(a), inflammation, semaglutide, biopharmaceutical, clinical-stage, autoimmune diseases, inflammatory diseases